1. 83314-01-6
2. Bryostatin-1
3. Nsc 339555
4. Chembl449158
5. Chebi:88353
6. 37o2x55y9e
7. Bryostatin
8. Nsc-339555
9. 2,4-octadienoic Acid, (1s,3s,5z,7r,8e,11s,12s,13e,15s,17r,21r,23r,25s)-25-(acetyloxy)-1,11,21-trihydroxy-17-((1r)-1-hydroxyethyl)-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo(21.3.1.13,7.111,15)nonacos-8-en-12-yl Ester, (2e,4e)-
10. Unii-37o2x55y9e
11. Ncgc00181150-01
12. Brn 4349157
13. Bryostatin 1 [mi]
14. Dsstox_cid_26876
15. Dsstox_rid_81981
16. Dsstox_gsid_46876
17. Schembl182960
18. Bryostatin 1 [who-dd]
19. Dtxsid8046876
20. Bryostatin 1, >=99%, Solid
21. Tox21_112754
22. Bdbm50258529
23. Bmy-45618
24. Zinc169357315
25. Bryostatin 1 - Cas 83314-01-6
26. (1s-(1r*,3r*,5z,7s*,8e,11r*,12r*(2e,4e),13e,15r*,17s*(s*),21s*,23s*,25r*))-25-(acetyloxy)-1,11,21-trihydroxy-17-(1-hydroxyethyl)-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo(21.3.1.13,7.111,15)nonacos-8-en-12-yl 2,4-octadienoate
27. 2,4-octadienoic Acid, 25-(acetyloxy)-1,11,21-trihydroxy-17-(1-hydroxyethyl)-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo(21.3.1.13,7.111,15)nonacos-8-en-12-yl Ester, (1s-(1r*,3r*,5z,7s*,8e,11r*,12r*(2e,4e),13e,15r*,17s*(s*),21s*,23s*,25r*))-
28. Cas-83314-01-6
29. Hy-105231
30. Cs-0025440
31. Q27095907
32. (1s,3s,5z,7r,8e,11s,12s,13e,15s,17r,21r,23r,25s)-25-(acetyloxy)-1,11,21-trihydroxy-17-[(1r)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.1(3,7).1(11,15)]nonacos-8-en-12-yl (2e,4e)-octa-2,4-dienoate
33. (1s,3s,5z,7r,8e,11s,12s,13e,15s,17r,21r,23r,25s)-25-(acetyloxy)-1,11,21-trihydroxy-17-[(1r)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl-(2e, 4e)-2,4-octadienoic Acid Ester
34. [(1s,3s,5z,7r,8e,11s,12s,13e,15s,17r,21r,23r,25s)-25-acetyloxy-1,11,21-trihydroxy-17-[(1r)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl] (2e,4e)-octa-2,4-dienoate
| Molecular Weight | 905.0 g/mol |
|---|---|
| Molecular Formula | C47H68O17 |
| XLogP3 | 4 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 17 |
| Rotatable Bond Count | 13 |
| Exact Mass | 904.44565070 g/mol |
| Monoisotopic Mass | 904.44565070 g/mol |
| Topological Polar Surface Area | 240 Ų |
| Heavy Atom Count | 64 |
| Formal Charge | 0 |
| Complexity | 1830 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 11 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 5 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Adjuvants, Immunologic
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
LOOKING FOR A SUPPLIER?
